Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Keyphrases

• Postmenopausal Women 100%
• Women with Breast Cancer 100%
• Randomized Phase III Trial 100%
• Letrozole 100%
• Continued Use 19%
• Disease-free Survival 14%
• Adverse Events 9%
• Intention-to-treat 9%
• Intermittent Use 9%
• Breast Cancer Research 9%
• Radiotherapy 4%
• Breast Cancer 4%
• Informed Consent 4%
• Patient Selection 4%
• Intervention Group 4%
• Recurrent Disease 4%
• Tertiary Care Hospital 4%
• Hypertension 4%
• Hazard Ratio 4%
• Treatment Group 4%
• Reintroduction 4%
• Selective Estrogen Receptor Modulators 4%
• Aromatase Inhibitors 4%
• Positive Lymph Nodes 4%
• Operable Breast Cancer 4%
• Hormone Receptor-positive 4%
• Log-rank Test 4%
• Local Treatment 4%
• Safety Analysis 4%
• Block Size 4%
• Treatment Assignment 4%
• Hormone Receptor-positive Breast Cancer 4%
• Permuted Block 4%
• Non-adherent 4%
• Arthralgia 4%
• Novartis 4%
• Endocrine Therapy 4%
• EudraCT 4%
• Treatment Breaks 4%
• Internet-based Systems 4%
• Cerebrovascular Ischemia 4%
• Alternative Schedule 4%
• Adjuvant Endocrine Therapy 4%
• Principal Investigator 4%
• Cardiac Ischemia 4%
• CNS Hemorrhage 4%
• Intention-to-treat Principle 4%
• Institutional Balancing 4%
• Breast Cancer Outcomes 4%
• Trial Participation 4%
• Primary Care Centers 4%
• Month of Year 4%
• Academic Primary Care 4%
• Intermittent Administration 4%
• Breast Cancer Susceptibility 4%
• Secondary Care Center 4%
• Extended Adjuvant Endocrine Therapy 4%
• Treatment Surgery 4%
• Extended Use 4%
• Lymph Node-positive Breast Cancer 4%

Medicine and Dentistry

• Breast Cancer 100%
• Postmenopause 100%
• Letrozole 100%
• Disease Free Survival 14%
• Intention-to-Treat Analysis 14%
• Adverse Event 9%
• Hormone Receptor 9%
• Adjuvant Endocrine Therapy 9%
• Informed Consent 4%
• Hormone Therapy 4%
• Recurrent Disease 4%
• Bleeding 4%
• Lymph Node 4%
• Brain Ischemia 4%
• Tertiary Care 4%
• Hazard Ratio 4%
• Arthralgia 4%
• Heart Muscle Ischemia 4%
• Selective Estrogen Receptor Modulator 4%
• Aromatase Inhibitor 4%
• Local Therapy 4%
• Log Rank Test 4%
• Primary Health Care 4%
• Secondary Care 4%
• Cancer Resistance 4%
• Radiation Therapy 4%
• Treatment Group 4%